Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes

J Diabetes Complications. 2016 May-Jun;30(4):716-22. doi: 10.1016/j.jdiacomp.2015.12.023. Epub 2015 Dec 24.

Abstract

Aim: We aimed to validate the performance cooling detection thresholds (CDT) to detect diabetic sensorimotor polyneuropathy (DSP) in type 2 diabetes.

Methods: Two hundred and twenty participants with type 2 diabetes underwent clinical and electrophysiological examinations including 3 small fiber function tests: CDT, heart rate variability (HRV) and LDIFLARE. Clinical DSP was defined by consensus criteria whereas preclinical DSP was defined by presence of at least one electrophysiological abnormality. Area under the curve (AUC) and optimal thresholds were determined by receiver operating characteristic curves.

Results: Participants were aged 63 ± 11 years with mean HbA1c of 7.5 ± 1.6%. The 139 (63%) clinical DSP cases had mean CDT values of 18.3 ± 8.9°C; the 52 (24%) preclinical DSP cases had 25.3 ± 3.5°C; and the 29 (13%) controls had 27.1 ± 3.8°C; (p-value<0.02 for all comparisons). For identification of clinical DSP cases, AUCCDT was 0.79 which exceeded AUCHRV (0.60, p=<0.0001) and AUCLDI FLARE (0.69, p=0.0003), optimal threshold <22.8°C (64% sensitivity, 83% specificity). Preclinical DSP AUCCDT was 0.80, also exceeding the other 2 measures (p<0.02 for both comparisons), optimal threshold ≤27.5°C (83% sensitivity, 72% specificity).

Conclusions: CDT had good diagnostic performance for identification of both clinical and preclinical neuropathy in type 2 diabetes. Its use as a non-invasive screening tool should be considered for research and clinical practice.

Keywords: Cooling detection threshold; Diabetic neuropathy; Diagnostic tests; Quantitative sensory testing; Type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Aged
  • Asymptomatic Diseases*
  • Biomarkers
  • Cohort Studies
  • Cold Temperature
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Neuropathies / diagnosis*
  • Early Diagnosis
  • Glycated Hemoglobin / analysis
  • Hospitals, General
  • Hospitals, Urban
  • Humans
  • Middle Aged
  • Ontario
  • Outpatient Clinics, Hospital
  • Polyneuropathies / complications
  • Polyneuropathies / diagnosis*
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Sensory Thresholds

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human